Marta Broto Aviles

Dr. Marta Broto Aviles

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MAMarta Broto Aviles
Marta Broto Aviles
MKMichael M. Kaminski
Michael M. Kaminski
CAChristopher Adrianus
Christopher Adrianus
NKNayoung Kim
Nayoung Kim
RGRobert Greensmith
Robert Greensmith
MSMolly M. Stevens
Molly M. Stevens

10 May 2017 in The Analyst
Verified
Journal Article
Closed access
PDF file
MAMarta Broto Aviles
Marta Broto Aviles
RMRita McCabe
Rita McCabe
RGRoger Galve
Roger Galve
M Pilar MarcoM Pilar Marco
M Pilar Marco
Cancer is a group of diseases in which abnormal cells grow and divide without control, with the potential to invade other parts of the body. Chemotherapy is a type of treatment that uses chemical agents to treat cancer. These drugs are toxic and produce undesirable adverse drug reactions due to their narrow therapeutic window and highly variable pharmacokinetics, thus, they need to be monitored to establish personalized treatment to achieve maximal efficiency and reduce drug toxicity. Nowadays, therapeutic drug monitoring (TDM) is not routinely used for chemotherapy agents, however, TDM has the potential to improve the clinical benefit of chemotherapy drugs. Tegafur, a prodrug of 5-fluorouracil (5FU), is one of the main anti-cancer drugs used worldwide. Herein, a reproducible and sensitive indirect competitive ELISA has been developed and validated in plasma samples. The assay reports an IC50 of 35.6 nM, reaching a limit of detection of 2.7 nM. It is highly reproducible and does not show cross-reactivity with any related compound. In summary, this assay provides a sensitive, accurate and high throughput analytical method for tegafur quantification in plasma, which fits TDM requirements.

1 May 2015 in Food Control
Verified
Journal Article
Closed access
MAMarta Broto Aviles
Marta Broto Aviles
SMSonia Matas
Sonia Matas
RBRuth Babington
Ruth Babington
M Pilar MarcoM Pilar Marco
M Pilar Marco
RGRoger Galve
Roger Galve

1 August 2017 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Open access
MAMarta Broto Aviles
Marta Broto Aviles
RGRoger Galve
Roger Galve
M Pilar MarcoM Pilar Marco
M Pilar Marco
Chemotherapy is the use of chemical substances to treat cancer. However, traditional chemotherapeutic agents do not show sufficient specificity for the cancer cells, which means that also healthy cells are strongly affected by these treatments. In parallel, manufacturers and health-care workers are continuously exposed to these cytostatic drugs through the usual procedures. Thus, there is a need to control the real internal dose received by this sector. Bioanalytical techniques may show great potential as tools for establishing a more personalized treatment procedure since therapeutic drug monitoring (TDM) could support clinicians on making and establishing decisions adapted to each patient. Similarly, these bioanalytical procedures may be implemented on those occupational sectors in which risk for exposure to these hazardous drugs exists. In this review, we present the overall situation in that respect and provide information of the bioanalytical techniques reported up to date for the most important cytostatic families. © 2017 Elsevier B.V.The Nb4D group (formerly Applied Molecular Receptors group, AMRg) is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (expedient: 2014 SGR 1484). CIBER-BBN is an initiative funded by the Spanish National Plan for Scientific and Technical Research and Innovation 2013–2016, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions are financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. This work was performed as part of a research contract with CETEMMSA Technological Center (part of the EURECAT Technology Center of Catalonia). Marta Broto wishes to thank the FPI-fellowship (BES-2013-062819) from the Spanish Ministry of Economy and Competitiveness.Peer reviewe

16 July 2019 in The Analyst
Verified
Journal Article
Closed access
PDF file
MAMarta Broto Aviles
Marta Broto Aviles
RMRita McCabe
Rita McCabe
RGRoger Galve
Roger Galve
M Pilar MarcoM Pilar Marco
M Pilar Marco
Personalized medicine is pushing forward new diagnostic techniques to aid in controlling drug therapeutic levels and their toxic effects.

13 February 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
SHSilke Häusler
Silke Häusler
LSLinda Schönborn
Linda Schönborn
JGJohann Gradl
Johann Gradl
JCJanne Cadamuro
Janne Cadamuro
KSKatja Steinbrücker
Katja Steinbrücker
TTThomas Thiele
Thomas Thiele